CIK 0001531177
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Sight Sciences, Inc.
Sign in to watch- Ticker
- SGHT
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 800625749
- Phone
- +1 415-889-0550
- Business address
- 4040 CAMPBELL AVE,, SUITE 100, MENLO PARK, CA, 94025
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $652,777
- in 5 filings, $653K under 10b5-1 plans
Net −$652,777. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Badawi Paul −$268K President and CEO sold <1% of stake
- Bauerlein Alison −$224K Chief Operating Officer sold 4% of stake
- Badawi David −$71K Chief Technology Officer sold <1% of stake
- Rodberg James −$64K Chief Financial Officer sold 3% of stake
- Taylor Brenton −$26K EVP, Operations & R&D sold 1% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-07-19 | Selnick Jesse Chief Financial Officer | Conversion · Series A Redeemable Convertible Preferred Stock | −869,565 | 0 | ||
| 2021-07-19 | Selnick Jesse Chief Financial Officer | Conversion · Series B Redeemable Convertible Preferred Stock | −118,494 | 0 | ||
| 2021-07-19 | Selnick Jesse Chief Financial Officer | Conversion · Series C Redeemable Convertible Preferred Stock | −121,725 | 0 | ||
| 2021-07-19 | Offer Andrew Director | Conversion | +3,162 | 3,162 | ||
| 2021-07-19 | Offer Andrew Director | Conversion | +2,225,752 | 2,355,062 | ||
| 2021-07-19 | Offer Andrew Director | Conversion · Series C Preferred Stock | −1,581 | 0 | ||
| 2021-07-19 | Offer Andrew Director | Conversion · Series A Redeemable Convertible Preferred Stock | −1,086,956 | 0 | ||
| 2021-07-19 | Offer Andrew Director | Conversion · Series B Redeemable Convertible Preferred Stock | −25,920 | 0 | ||
| 2021-07-19 | Encrantz Staffan Director | Conversion | +2,970,070 | 2,970,070 | ||
| 2021-07-19 | Encrantz Staffan Director | Conversion | +632,456 | 632,456 | ||
| 2021-07-19 | Encrantz Staffan Director | Conversion · Series A Redeemable Convertible Preferred Stock | −724,637 | 0 | ||
| 2021-07-19 | Encrantz Staffan Director | Conversion · Series B Redeemable Convertible Preferred Stock | −98,745 | 0 | ||
| 2021-07-19 | Encrantz Staffan Director | Conversion · Series C Redeemable Convertible Preferred Stock | −661,653 | 0 | ||
| 2021-07-19 | Encrantz Staffan Director | Conversion · Series C Redeemable Convertible Preferred Stock | −316,228 | 0 | ||
| 2021-07-19 | Hicks Mack H. Director | Conversion | +2,669,530 | 2,669,530 | ||
| 2021-07-19 | Hicks Mack H. Director | Conversion | +1,717,140 | 1,717,140 | ||
| 2021-07-19 | Hicks Mack H. Director | Conversion · Series A Redeemable Convertible Preferred Stock | −3,768,112 | 0 | ||
| 2021-07-19 | Hicks Mack H. Director | Conversion · Series B Redeemable Convertible Preferred Stock | −513,472 | 0 | ||
| 2021-07-19 | Hicks Mack H. Director | Conversion · Series B Redeemable Convertible Preferred Stock | −2,764,860 | 0 | ||
| 2021-07-19 | Hicks Mack H. Director | Conversion · Series C Redeemable Convertible Preferred Stock | −1,057,476 | 0 |
Page 15 of 16 · 302 trades